Open in PodwiseOpen

Podcast cover

BiotechTV · News

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Episodes

BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes

BIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac

BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science

BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year

BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after

BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time

BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF

BIO-Europe 2025: Valneva's partner Pfizer has been running a big trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year

Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases

BIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants

BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today

Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.

BiotechTV visited South San Francisco based Noetik and saw how they are digitizing tumor samples and using AI to sort through the complexity of the biology for drug discovery

Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.

Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes

Hemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need.

Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development

Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

Page 11

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise